Isotretinoin - Cipher Pharmaceuticals

Drug Profile

Isotretinoin - Cipher Pharmaceuticals

Alternative Names: Absorica; CIP-isotretinoin; Epuris; Isotretinoin - Cipher; Lisacne-CIP; Semi-liquid isotretinoin capsules - Cipher

Latest Information Update: 21 Aug 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Cipher Pharmaceuticals
  • Developer Andromaco; Cipher Pharmaceuticals; Sun Pharmaceutical Industries
  • Class Antiacnes; Keratolytics; Retinoids
  • Mechanism of Action Retinoic acid receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Marketed Acne

Most Recent Events

  • 30 Jul 2018 Cipher and Sun Pharmaceutical amend development and marketing agreement
  • 09 Jan 2018 Isotretinoin licensed for marketing, selling and distribution to Italmex Pharma in Mexico
  • 15 Mar 2016 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top